Anthrax is known to be caused by the bacteria Bacillus anthracis, which is quite germicidal in nature. It has made its mark over the years as a very menacing disease that has endangered mankind in many ways. Our firm offers services on anthrax vaccine and therapeutics development within a single functional unit.
Introduction to Anthrax
Anthrax is again a very infectious disease and is caused by the bacteria Bacillus anthracis that has spore. This organism Bacillus anthracis has potential to infect humans via multiple routes such as cutaneous, inhalation and gastrointestinal, which can lead to a spectrum of diseases, some of which can be dangerously accelerated to life threatening systemic onsets.
Anthrax pneumonia has proven to be a dire threat and Anthrax itself has made it possible for both humans and livestock to perish. Up till now, there has been an effective medical management with the help of tools to diagnose, therapeutically and preventive. There is still a threat of anthrax being use as a bioweapon and hence this justifies the need of more researches on upgrading the vaccines of anthrax and enhancing therapy for curing it.
Fig. 1 The life cycle of Bacillus anthracis in nature. (Salinas-Estrella E., et al., 2022)
Vaccine Development for Anthrax
When examining the anatomy of the Bacillus anthracis, research on anthrax vaccine has confirmed that it is a clonal organism. That is, the gene pagA, which is known to be highly conserved and responsible for Protective Antigen, has been a gene of interest for used gene in Anthrax vaccine development. Understanding this has led to the development of PA anthrax based vaccines, which have the capability of protecting a variety of animal species from various strains of B. anthracis around the world.
1955-1960
Brachman Field Evaluation Study
1999
Congressional Mandate for AVRP
2002
AVRP Enrollment Initiated
2008
Reduction of PrEP priming series and IM administration approved
2012
3-IM priming approved
Therapeutics Development for Anthrax
Therapeutics-measures against Bacillus anthracis include administering antibiotics such as quarternary ammonium compounds cutaneous and administration of vaccine to animals and farmers who handle meat. Studies have been conducted using various antibiotics such as penicillin and aminoglycosides and it was concluded that these antibiotics along with carbapenems as well as quinolones can be successful in many areas alongside drug resistant anthrax. Evidence based systemic cuts such as creaming inhalational and mensingeal are recommended for them.
In addition, Studies also evaluate additional therapies such as corticosteroids for edema management, surgical debridement of infected areas and the combination of antitoxin therapies such as polyclonal anthrax immune globulin with monoclonal antitoxins.
To find out more about the comprehensive therapy development services provided by our company follow the link below.
Our Services
Our company has developed a wide range of vaccines and therapies against anthrax and we focus on its leverage in drug and preclinical mussel research design meaning we take care of all aspects of development and have side preclinical capabilities through the must mean our clients have the best possible up to date experience and capabilities from the clients perspective.
- Aerosol Exposure Models
- Transtracheal Injection Models
- Peroral Intubation Models
- Intranasal Inoculation Models
Optional Species: murine, rabbit, guinea pig, nonhuman primate, and rat
The proficient experts in our state-of-the-art preclinical research facilities focus on animal research involving anthrax vaccine candidates and therapeutic agents. Preclinical studies of broad scope make it feasible to devise safe and efficient therapeutic agents and vaccines. Should you wish to procure any of these services, we would be more than willing to assist you.
References
- Salinas-Estrella Elizabeth, et al. "Bovine Anaplasmosis: Will there ever be an almighty effective vaccine?." Frontiers in Veterinary Science 9 (2022): 946545.
- Atif, Farhan Ahmad, Kashif Hussain, and Saba Mehnaz. "Strategies for prevention and control of anaplasmosis: at human-animal interface." Pakistan Journal of Agricultural Sciences 58.5 (2021).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
